Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross et al. • 2010 • Obesity (Silver Spring). 2010;18(12):2295-300.
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 151 entries already.
Entries by jeremiah@devisedesigns.com
Mifepristone treatment of olanzapine-induced weight gain in healthy men.
Gross et al. • 2009 • Adv Ther. 2009;26(10):959-69.
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.
Steroid receptors aplenty in prostate cancer.
Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.
“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.
Minireview: nuclear receptors and breast cancer.
Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.
The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor et al. • 2013 • Clin Cancer Res. 2013;19(22):6163-72.